About the Company
Michael "Mike" Weston Bonney is an American businessman and former pharmaceutical executive. Bonney was the president and chief executive officer of Cubist Pharmaceuticals, from 2003 until his retirement in 2014 coinciding with the company being acquired by Merck & Co. for $9.5 billion. Bonney, a native of the Greater Boston area, graduated from Bates College before entering the pharmaceutical industry. He was hired by Biogen in 1995 eventually becoming the company's vice president for Sales and Marketing. During his tenure at the company he developed Avonex, which was according to MarketWatch, one of the most successful drugs in biotechnology history. He was appointed the chief operating officer of Cubist Pharmaceuticals in 2003 and served in the position for one year before becoming chief executive. His tenure as CEO saw mixed profit levels, criticism, and increased market volatility as well as the development and release of Cubicin, the most profitable launch of an antibiotic in the history of the United States. Bonney serves as an advisor to former Prime Minister David Cameron's Commission on Antimicrobial Resistance (AMR).
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on X4 Pharmaceuticals, Inc
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Report Preview: What To ...
X4 Pharmaceuticals Inc (NASDAQ:XFOR) is set to release its Q4 2024 earnings on Mar 25, 2025. The consensus estimate for Q4 2024 revenue is $1.04 million, and the earnings are expected to come in ...
X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 ...
On March 21, 2024, X4 Pharmaceuticals Inc (NASDAQ:XFOR) released its 8-K filing, announcing its financial results for the fourth quarter and full year ended December 31, 2023. The late-stage ...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing ...
BOSTON, Aug. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that ...
X4 Pharmaceuticals Granted New Composition of Matter Patent ... - Nasdaq
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the United States ...
X4 Pharmaceuticals Appoints William E. Aliski to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare ...
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results ...
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results - Earnings Call Transcript Nov. 10, 2019 2:02 AM ET X4 Pharmaceuticals, Inc. (XFOR) Stock XFOR SA Transcripts 154.11K Follower s ...
What You Need To Know About X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR ...
The big shareholder groups in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership.
X4 Pharmaceuticals to Present at Stifel 2019 Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare ...
X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of ...
X4 Pharmaceutical’s lead product candidate, mavorixafor (X4P-001), is a potentially first-in-class, once-daily, oral inhibitor of CXCR4, currently in Phase 3 development for the treatment of ...
X4 Pharmaceuticals Inc. (XFOR) Stock Price Today - WSJ
View the latest X4 Pharmaceuticals Inc. (XFOR) stock price, news, historical charts, analyst ratings and financial information from WSJ.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, ...
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q2 2020 Results ...
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ETCompany ParticipantsCandice Ellis - Director, Corporate ...
Similar Companies
Loading the latest forecasts...